Qiagen Expands Companion Diagnostic Portfolio

Qiagen has received approval of its Therascreen EGFR Mutation Detection Kit RGQ from Japanese regulatory authorities.

The company said that the test can be used to personalize treatment for various cancer drug targeting EGFR. Qiagen characterized Japan has "one of the world’s largest markets for companion diagnostic tests."

The EGFR test marks Qiagen's second approval in Japan. In April 2011, Japanese health regulators approved Qiagen's Therascreen KRAS Mutation Detection Kit.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.